Real‐world evidence demonstrates an appropriate atrial fibrillation population for hybrid convergent approach versus stand‐alone cryoballoon ablation: A long‐term safety and efficacy study
Journal of Cardiovascular Electrophysiology · 2024
DOI: 10.1111/jce.16327 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2024. Verfasst von Christian Lorenzo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Electrophysiology, Orlando Health Heart and Vascular Institute, Orlando, Florida, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cryosurgery, Pulmonary Veins, Recurrence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
A hybrid convergent approach (endocardial and epicardial ablation) demonstrated superior effectiveness in a recent randomized study for long‐standing persistent atrial fibrillation (LSPAF). Yet, there is a lack of real‐world, long‐term evidence as to which patients are best candidates for a hybrid convergent approach compared to standard endocardial cryoballoon pulmonary vein isolation (CB PVI). Methods and Results This single‐center, retrospective analysis spanning from 2010 to 2015 compared two distinctly different atrial fibrillation (AF) cohorts; one treated with stand‐alone cryoablation and one treated with a hybrid convergent approach. Baseline characteristics described candidates for each approach. The following criteria were utilized to determine CB PVI candidacy: (1) paroxysmal AF (PAF) (stage 3A) with failed class I/III antiarrhythmic drug (AAD) or (2) persistent/LSPAF (stage 3B/3C/3D) with failed class I/III AAD unwilling to undergo hybrid procedure. Selection criteria for the hybrid procedure included: (1) PAF refractory to both class I/III AAD and prior CB PVI (stage 3D) or (2) persistent/LSPAF (stage 3B/3C/3D) with failed class I/III AAD agreeable to hybrid procedure. Prior sternotomy was excluded. Serial electrocardiograms and continuous monitoring evaluated primary efficacy outcome of time‐to‐first recurrence of atrial arrhythmia after a 90‐day blanking period. Secondary outcomes were procedure‐related complications and AAD use (at discharge, 12, and 36 months). Kaplan‐Meier methods evaluated arrhythmia recurrence. Of 276 patients, 197 (64.2 ± 10.6 years old; 66.5% male; 74.1% 3A‐PAF; 18.3% 3B/3D‐persistent AF; 1.0% 3C‐LSPAF; 6.6% undetermined) underwent CB PVI and 79 (61.4 ± 8.1 years old; 83.5% male; 41.8% 3D‐PAF; 45.5% 3B/3D‐persistent AF; 12.7% 3C/3D‐LSPAF) underwent hybrid procedure. Arrhythmia freedom through 36 months was 55.2% for CB PVI and 50.4% for hybrid ( p = .32). Class I AAD utilization at discharge occurred in 38 (19.3%) patients in the CB PVI group and 5 (6.3%) patients in the hybrid group ( p = .01). CB PVI class I AAD utilization at 12 months occurred in 14 (9.0) patients versus 0 patients for hybrid convergent ( p = .004). Patients with one or more adverse event were as follows: two (1.0%) in the CB PVI group (both transient phrenic nerve palsy) and three (3.7%) in the hybrid group (two with significant bleeding and one with wound infection) ( p = .14).
Conclusion
This study demonstrated that patients with more complex forms of AF (3D‐PAF or 3B/3C/3D‐persistent/LSPAF) could be well managed with a convergent approach. In a real‐world evaluation, outcomes match safety and efficacy thresholds achieved for patients with earlier, less complex AF etiologies treated by CB PVI alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology and Electrophysiology, Orlando Health Heart and Vascular Institute, Orlando, Florida, USA.
ORCID-Profile: Christian Lorenzo
Zitieren
APA
Lorenzo, C., Ortiz-Gonzalez, Y., Hill, D., Kinaga, J., Filart, L., Bello, D., Duran, A., Bott, J., Patel, S., Sendin, M. J., & Filart, R. (2024). Real‐world evidence demonstrates an appropriate atrial fibrillation population for hybrid convergent approach versus stand‐alone cryoballoon ablation: A long‐term safety and efficacy study. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16327
Vancouver
Lorenzo C, Ortiz-Gonzalez Y, Hill D, Kinaga J, Filart L, Bello D, et al. Real‐world evidence demonstrates an appropriate atrial fibrillation population for hybrid convergent approach versus stand‐alone cryoballoon ablation: A long‐term safety and efficacy study. Journal of Cardiovascular Electrophysiology. 2024. doi:10.1111/jce.16327
BibTeX
@article{Lorenzo2024,
author = {Lorenzo, Christian and Ortiz-Gonzalez, Yahaira and Hill, Dustin and Kinaga, Jennifer and Filart, Lauren and Bello, David and Duran, Aurelio and Bott, Jeffery and Patel, Shivangi and Sendin, Mary Janette and Filart, Roland},
title = {Real‐world evidence demonstrates an appropriate atrial fibrillation population for hybrid convergent approach versus stand‐alone cryoballoon ablation: A long‐term safety and efficacy study},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2024},
doi = {10.1111/jce.16327}
}
EUVIMED